ROZINUS GOLD Capsules
Generic Name:
Aspirin 75 mg + Clopidogrel 75 mg + Rosuvastatin 10 mg
Therapeutic Group:
Cardiovascular Protection
Drug Category:
Antiplatelet Agents + Lipid-Lowering Agent (Statin)
Content / Composition:
Each capsule contains:
Aspirin ……………………………………… 75 mg
Clopidogrel ……………………………… 75 mg
Rosuvastatin …………………………… 10 mg
Excipients ………………………………… q.s.
Indications:
ROZINUS GOLD is indicated for:
Prevention of myocardial infarction (heart attack) and stroke
Secondary prevention in coronary artery disease (CAD)
Post-angioplasty / stent placement management
Atherosclerotic cardiovascular disease (ASCVD)
Patients with dyslipidemia and high cardiovascular risk
Dosage:
One capsule once daily or as directed by the physician
Preferably taken at the same time each day
Long-term therapy based on clinical condition
Contraindications:
Hypersensitivity to aspirin, clopidogrel, or rosuvastatin
Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage)
Severe liver disease
Pregnancy and breastfeeding
History of statin-induced myopathy
Administration:
Administer orally with water
Can be taken with or without food
Swallow whole; do not crush or chew
Drug Interactions:
Increased bleeding risk with anticoagulants (warfarin, heparin)
Interaction with NSAIDs and corticosteroids
Rosuvastatin interaction with cyclosporine and certain antivirals
Alcohol may increase risk of liver side effects
Compatibility:
Suitable for combination with antihypertensive and antidiabetic medications
Compatible with standard cardiovascular therapy protocols
Stability / Storage:
Store below 25°C
Protect from moisture, heat, and light
Keep out of reach of children
Precautions:
Monitor for bleeding tendencies
Periodic liver function tests recommended
Evaluate muscle pain or weakness (risk of myopathy)
Use cautiously in elderly patients
Do not discontinue abruptly without medical advice
Side Effects:
Common:
Gastric irritation
Headache
Nausea
Dizziness
Uncommon:
Bleeding or bruising
Elevated liver enzymes
Muscle pain
Serious (Rare):
Severe bleeding
Rhabdomyolysis
Allergic reactions
Important Note:
ROZINUS GOLD is a fixed-dose combination for cardiovascular risk reduction and should be used under strict medical supervision. This information is intended for healthcare professionals and educational purposes only.

ROZINUS 20 mg Tablets
Generic Name:
Rosuvastatin 20 mg
Therapeutic Group:
Lipid-Lowering Agent
Drug Category:
HMG-CoA Reductase Inhibitor (Statin)
Content / Composition:
Each film-coated tablet contains:
Rosuvastatin …………………………… 20 mg
Excipients ……………………………… q.s.
Indications:
ROZINUS is indicated for:
Hypercholesterolemia (elevated LDL cholesterol)
Mixed dyslipidemia
Prevention of cardiovascular diseases (heart attack, stroke)
Atherosclerotic cardiovascular disease (ASCVD)
Reduction of total cholesterol, LDL, and triglycerides; increase of HDL
Dosage:
Initial dose: 5–10 mg once daily
Usual dose: 10–20 mg once daily
Maximum dose: 40 mg/day (under specialist supervision)
Dose adjustment required in renal impairment
As directed by the physician
Contraindications:
Hypersensitivity to rosuvastatin
Active liver disease
Severe renal impairment (without dose adjustment)
Pregnancy and breastfeeding
History of statin-induced myopathy
Administration:
Administer orally with water
Can be taken at any time of the day, with or without food
Swallow whole; do not crush or chew
Drug Interactions:
Increased risk of myopathy with cyclosporine, fibrates, or certain antivirals
Interaction with warfarin (monitor INR)
Antacids may reduce absorption (separate dosing)
Avoid excessive alcohol consumption
Compatibility:
Suitable for combination with antihypertensive and antidiabetic agents
Compatible with cardiovascular risk management protocols
Stability / Storage:
Store below 25°C
Protect from light, heat, and moisture
Keep out of reach of children
Precautions:
Monitor liver function before and during treatment
Evaluate muscle symptoms (risk of myopathy/rhabdomyolysis)
Use cautiously in elderly patients
Lifestyle modification (diet & exercise) should continue
Do not use in pregnancy
Side Effects:
Common:
Headache
Muscle pain (myalgia)
Abdominal pain
Nausea
Uncommon:
Elevated liver enzymes
Weakness
Constipation
Serious (Rare):
Rhabdomyolysis
Severe liver injury
Hypersensitivity reactions
Important Note:
ROZINUS is a potent statin used for cholesterol control and cardiovascular risk reduction. It should be used under medical supervision. This information is intended for healthcare professionals and educational purposes only.

ROZINUS 10 mg Tablets
Generic Name:
Rosuvastatin 10 mg
Therapeutic Group:
Lipid-Lowering Agent
Drug Category:
HMG-CoA Reductase Inhibitor (Statin)
Content / Composition:
Each film-coated tablet contains:
Rosuvastatin …………………………… 10 mg
Excipients ……………………………… q.s.
Indications:
ROZINUS is indicated for:
Primary hypercholesterolemia
Mixed dyslipidemia
Prevention of cardiovascular events (heart attack, stroke)
Atherosclerotic cardiovascular disease (ASCVD)
Reduction of LDL cholesterol, total cholesterol, and triglycerides
Increase of HDL cholesterol
Dosage:
Initial dose: 5–10 mg once daily
Maintenance dose: 10–20 mg once daily
Maximum dose: 40 mg/day (under specialist supervision)
Dose adjustment required in renal impairment
As directed by the physician
Contraindications:
Hypersensitivity to rosuvastatin
Active liver disease
Severe renal impairment (without dose adjustment)
Pregnancy and breastfeeding
History of statin-induced muscle disorders
Administration:
Administer orally with water
Can be taken at any time of the day, with or without food
Swallow whole; do not crush or chew
Drug Interactions:
Increased risk of myopathy with fibrates, cyclosporine, or certain antivirals
Warfarin (monitor INR)
Antacids may reduce absorption (administer separately)
Alcohol increases risk of liver toxicity
Compatibility:
Suitable for combination with antihypertensive and antidiabetic medications
Compatible with comprehensive cardiovascular management plans
Stability / Storage:
Store below 25°C
Protect from light, heat, and moisture
Keep out of reach of children
Precautions:
Monitor liver function before and during treatment
Assess muscle symptoms (risk of myopathy/rhabdomyolysis)
Use cautiously in elderly patients
Lifestyle modification (diet, exercise) should be continued
Not to be used during pregnancy
Side Effects:
Common:
Headache
Muscle pain (myalgia)
Abdominal pain
Nausea
Uncommon:
Elevated liver enzymes
Fatigue
Constipation
Serious (Rare):
Rhabdomyolysis
Severe liver injury
Hypersensitivity reactions
Important Note:
ROZINUS is a potent statin used for cholesterol control and cardiovascular risk reduction. It should be used under medical supervision. This information is intended for healthcare professionals and educational purposes only.

Generic Name:
Glimepiride 4 mg
Therapeutic Group:
Antidiabetic Agent
Drug Category:
Sulfonylurea (Insulin Secretagogue)
Content / Composition:
Each tablet contains:
Glimepiride …………………………… 4 mg
Excipients ……………………………… q.s.
Indications:
DAIBET-G4 is indicated for:
Type 2 Diabetes Mellitus
Improvement of glycemic control when diet and exercise alone are insufficient
Can be used as monotherapy or in combination with metformin or insulin
Dosage:
Initial dose: 1–2 mg once daily
Maintenance dose: 1–4 mg once daily
Maximum dose: 8 mg/day
Dose should be individualized based on blood glucose levels
As directed by the physician
Contraindications:
Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal or hepatic impairment
Hypersensitivity to glimepiride or other sulfonylureas
Pregnancy and lactation
Administration:
Administer orally once daily
Take with breakfast or first main meal
Swallow whole with water
Avoid skipping meals to prevent hypoglycemia
Drug Interactions:
Increased hypoglycemic effect with insulin, metformin, NSAIDs, and some antibiotics
Reduced effect with corticosteroids, diuretics, and oral contraceptives
Alcohol may increase risk of hypoglycemia
Compatibility:
Suitable for combination with metformin, insulin, or other antidiabetic agents
Compatible with long-term diabetes management protocols
Stability / Storage:
Store below 25°C
Protect from moisture, heat, and light
Keep out of reach of children
Precautions:
Risk of hypoglycemia (especially in elderly or irregular meals)
Monitor blood glucose regularly
Use cautiously in renal or hepatic impairment
Patients should be educated about symptoms of hypoglycemia
Lifestyle modification (diet & exercise) is essential
Side Effects:
Common:
Hypoglycemia
Dizziness
Headache
Nausea
Uncommon:
Weight gain
Gastrointestinal disturbances
Serious (Rare):
Severe hypoglycemia
Allergic reactions
Liver dysfunction
Important Note:
DAIBET-G4 is an oral antidiabetic agent used for glycemic control in Type 2 Diabetes. It should be used under medical supervision. This information is intended for healthcare professionals and educational purposes only.

DAIBET-G3 Tablets
Generic Name:
Glimepiride 3 mg
Therapeutic Group:
Antidiabetic Agent
Drug Category:
Sulfonylurea (Insulin Secretagogue)
Content / Composition:
Each tablet contains:
Glimepiride …………………………… 3 mg
Excipients ……………………………… q.s.
Indications:
DAIBET-G3 is indicated for:
Type 2 Diabetes Mellitus
Improvement of glycemic control when diet and exercise are insufficient
Can be used alone or in combination with metformin or insulin
Dosage:
Initial dose: 1–2 mg once daily
Maintenance dose: 1–4 mg once daily
Maximum dose: 8 mg/day
Dose should be individualized based on blood glucose levels
As directed by the physician
Contraindications:
Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal or hepatic impairment
Hypersensitivity to glimepiride or sulfonylureas
Pregnancy and lactation
Administration:
Administer orally once daily
Take with breakfast or first main meal
Swallow whole with water
Avoid skipping meals to prevent hypoglycemia
Drug Interactions:
Increased hypoglycemic effect with insulin, metformin, NSAIDs, and some antibiotics
Reduced effect with corticosteroids, diuretics, and oral contraceptives
Alcohol may increase risk of hypoglycemia
Compatibility:
Suitable for combination with metformin, insulin, or other antidiabetic agents
Compatible with long-term diabetes management protocols
Stability / Storage:
Store below 25°C
Protect from moisture, heat, and light
Keep out of reach of children
Precautions:
Risk of hypoglycemia (especially in elderly or irregular meals)
Monitor blood glucose regularly
Use cautiously in renal or hepatic impairment
Patients should be educated about symptoms of hypoglycemia
Lifestyle modification (diet & exercise) is essential
Side Effects:
Common:
Hypoglycemia
Dizziness
Headache
Nausea
Uncommon:
Weight gain
Gastrointestinal disturbances
Serious (Rare):
Severe hypoglycemia
Allergic reactions
Liver dysfunction
Important Note:
DAIBET-G3 is an oral antidiabetic agent used for glycemic control in Type 2 Diabetes. It should be used under medical supervision. This information is intended for healthcare professionals and educational purposes only.

DAIBET-G2 Tablets
Generic Name:
Glimepiride 2 mg
Therapeutic Group:
Antidiabetic Agent
Drug Category:
Sulfonylurea (Insulin Secretagogue)
Content / Composition:
Each tablet contains:
Glimepiride …………………………… 2 mg
Excipients ……………………………… q.s.
Indications:
DAIBET-G2 is indicated for:
Type 2 Diabetes Mellitus
Improvement of glycemic control when diet and exercise alone are insufficient
Can be used as monotherapy or in combination with metformin or insulin
Dosage:
Initial dose: 1–2 mg once daily
Maintenance dose: 1–4 mg once daily
Maximum dose: 8 mg/day
Dose should be individualized based on blood glucose levels
As directed by the physician
Contraindications:
Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal or hepatic impairment
Hypersensitivity to glimepiride or sulfonylureas
Pregnancy and lactation
Administration:
Administer orally once daily
Take with breakfast or first main meal
Swallow whole with water
Avoid skipping meals to prevent hypoglycemia
Drug Interactions:
Increased hypoglycemic effect with insulin, metformin, NSAIDs, and certain antibiotics
Reduced effect with corticosteroids, diuretics, and oral contraceptives
Alcohol may increase risk of hypoglycemia
Compatibility:
Suitable for combination with metformin, insulin, or other antidiabetic agents
Compatible with long-term diabetes management protocols
Stability / Storage:
Store below 25°C
Protect from moisture, heat, and light
Keep out of reach of children
Precautions:
Risk of hypoglycemia (especially in elderly or irregular meals)
Regular monitoring of blood glucose is essential
Use cautiously in renal or hepatic impairment
Educate patients about signs of hypoglycemia
Lifestyle modification (diet & exercise) must be continued
Side Effects:
Common:
Hypoglycemia
Headache
Dizziness
Nausea
Uncommon:
Weight gain
Gastrointestinal disturbances
Serious (Rare):
Severe hypoglycemia
Allergic reactions
Liver dysfunction
Important Note:
DAIBET-G2 is an oral antidiabetic agent used for glycemic control in Type 2 Diabetes Mellitus. It should be used under medical supervision. This information is intended for healthcare professionals and educational purposes only.

DAIBET-M2 Tablets
Generic Name:
Glimepiride 2 mg + Metformin Hydrochloride 500 mg
Therapeutic Group:
Antidiabetic Combination
Drug Category:
Sulfonylurea (Insulin Secretagogue) + Biguanide
Content / Composition:
Each film-coated tablet contains:
Glimepiride …………………………… 2 mg
Metformin Hydrochloride ………… 500 mg
Excipients ……………………………… q.s.
Indications:
DAIBET-M2 is indicated for:
Type 2 Diabetes Mellitus
Patients inadequately controlled with monotherapy
Improvement of glycemic control (fasting and postprandial glucose)
Combination therapy to enhance insulin secretion and reduce hepatic glucose production
Dosage:
One tablet once or twice daily with meals
Dose should be individualized based on blood glucose levels
Maximum dose determined by physician
Gradual dose titration recommended
Contraindications:
Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal impairment (eGFR <30 mL/min)
Severe hepatic disease
Hypersensitivity to sulfonylureas or metformin
Conditions predisposing to lactic acidosis
Pregnancy and lactation
Administration:
Administer orally with meals to reduce gastrointestinal side effects
Swallow whole with water
Do not skip meals (risk of hypoglycemia)
Drug Interactions:
Increased hypoglycemic effect with insulin, NSAIDs, and certain antibiotics
Metformin interaction with contrast media (risk of lactic acidosis)
Reduced effect with corticosteroids, diuretics, and oral contraceptives
Alcohol increases risk of hypoglycemia and lactic acidosis
Compatibility:
Suitable for combination with insulin or other oral antidiabetic agents
Compatible with comprehensive diabetes management plans
Stability / Storage:
Store below 25°C
Protect from heat, moisture, and light
Keep out of reach of children
Precautions:
Risk of hypoglycemia (due to glimepiride)
Risk of lactic acidosis (due to metformin)
Monitor renal function regularly
Use cautiously in elderly patients
Suspend before major surgery or contrast imaging procedures
Lifestyle modification (diet & exercise) is essential
Side Effects:
Common:
Hypoglycemia
Gastrointestinal upset (nausea, diarrhea)
Headache
Dizziness
Uncommon:
Weight changes
Vitamin B12 deficiency (long-term use)
Serious (Rare):
Lactic acidosis
Severe hypoglycemia
Allergic reactions
Important Note:
DAIBET-M2 is a fixed-dose combination used for glycemic control in Type 2 Diabetes Mellitus. It should be used under strict medical supervision. This information is intended for healthcare professionals and educational purposes only.

EMPATIN-H Tablets
Generic Name:
Empagliflozin 25 mg + Linagliptin 5 mg
Therapeutic Group:
Antidiabetic Combination
Drug Category:
SGLT2 Inhibitor + DPP-4 Inhibitor
Content / Composition:
Each film-coated tablet contains:
Empagliflozin …………………………… 25 mg
Linagliptin ……………………………… 5 mg
Excipients ……………………………… q.s.
Indications:
EMPATIN-H is indicated for:
Type 2 Diabetes Mellitus
Improvement of glycemic control in adults inadequately controlled on monotherapy
Reduction of cardiovascular risk in patients with Type 2 Diabetes
Renal protection in diabetic patients (as part of comprehensive care)
Dosage:
One tablet once daily
Can be taken with or without food
Dose adjustment based on renal function and clinical response
As directed by the physician
Contraindications:
Hypersensitivity to empagliflozin or linagliptin
Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal impairment (eGFR <30 mL/min)
Pregnancy and lactation
Administration:
Administer orally with water
Take at the same time each day
Maintain adequate hydration
Drug Interactions:
Increased risk of hypoglycemia with insulin or sulfonylureas
Diuretics may increase risk of dehydration
Rifampicin may reduce linagliptin effectiveness
Monitor when used with antihypertensive drugs
Compatibility:
Suitable for combination with metformin, insulin, or other antidiabetic agents
Compatible with comprehensive diabetes management protocols
Stability / Storage:
Store below 25°C
Protect from light, heat, and moisture
Keep out of reach of children
Precautions:
Risk of dehydration and hypotension (due to SGLT2 inhibitor)
Monitor renal function regularly
Risk of genital and urinary tract infections
Monitor blood glucose levels regularly
Educate patients about signs of ketoacidosis (rare but serious)
Use cautiously in elderly patients
Side Effects:
Common:
Increased urination
Genital infections
Urinary tract infections
Headache
Uncommon:
Hypoglycemia (especially with combination therapy)
Dizziness
Dehydration
Serious (Rare):
Diabetic ketoacidosis
Severe infections
Allergic reactions
Important Note:
EMPATIN-H is a modern fixed-dose combination for Type 2 Diabetes offering glycemic control with cardiovascular and renal benefits. It should be used under medical supervision. This information is intended for healthcare professionals and educational purposes only.

SITA-H Tablets
Generic Name:
Sitagliptin 50 mg + Metformin Hydrochloride 850 mg
Therapeutic Group:
Antidiabetic Combination
Drug Category:
DPP-4 Inhibitor + Biguanide
Content / Composition:
Each film-coated tablet contains:
Sitagliptin ……………………………… 50 mg
Metformin Hydrochloride ………… 850 mg
Excipients ……………………………… q.s.
Indications:
SITA-H is indicated for:
Type 2 Diabetes Mellitus
Patients inadequately controlled with metformin or other oral antidiabetics
Improvement of glycemic control (fasting and postprandial glucose)
Combination therapy to enhance insulin secretion and reduce hepatic glucose production
Dosage:
One tablet twice daily with meals (or as directed by physician)
Dose should be individualized based on glycemic response
Gradual titration recommended to reduce gastrointestinal side effects
Contraindications:
Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal impairment (eGFR <30 mL/min)
Severe hepatic disease
Hypersensitivity to sitagliptin or metformin
Conditions predisposing to lactic acidosis
Pregnancy and lactation
Administration:
Administer orally with meals
Swallow whole with water
Avoid skipping meals
Drug Interactions:
Increased risk of hypoglycemia with insulin or sulfonylureas
Metformin interaction with iodinated contrast agents
Reduced efficacy with corticosteroids and diuretics
Alcohol increases risk of lactic acidosis
Compatibility:
Suitable for combination with insulin or other oral antidiabetic agents
Compatible with comprehensive diabetes management plans
Stability / Storage:
Store below 25°C
Protect from heat, moisture, and light
Keep out of reach of children
Precautions:
Risk of lactic acidosis (metformin component)
Monitor renal function regularly
Risk of pancreatitis (rare with sitagliptin)
Monitor blood glucose levels
Use cautiously in elderly patients
Suspend before surgery or contrast imaging procedures
Side Effects:
Common:
Gastrointestinal disturbances (nausea, diarrhea)
Headache
Hypoglycemia (with combination therapy)
Uncommon:
Dizziness
Fatigue
Serious (Rare):
Lactic acidosis
Pancreatitis
Hypersensitivity reactions
Important Note:
SITA-H is a fixed-dose combination for effective glycemic control in Type 2 Diabetes Mellitus. It should be used under medical supervision. This information is intended for healthcare professionals and educational purposes only.

SITA-H Tablets
Generic Name:
Sitagliptin 50 mg + Metformin Hydrochloride 500 mg
Therapeutic Group:
Antidiabetic Combination
Drug Category:
DPP-4 Inhibitor + Biguanide
Content / Composition:
Each film-coated tablet contains:
Sitagliptin ……………………………… 50 mg
Metformin Hydrochloride ………… 500 mg
Excipients ……………………………… q.s.
Indications:
SITA-H is indicated for:
Type 2 Diabetes Mellitus
Patients inadequately controlled on metformin or other oral antidiabetic agents
Improvement of glycemic control (fasting and postprandial glucose)
Combination therapy to enhance insulin secretion and reduce hepatic glucose production
Dosage:
One tablet twice daily with meals (or as directed by physician)
Dose should be individualized based on glycemic response
Gradual titration recommended to minimize gastrointestinal side effects
Contraindications:
Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal impairment (eGFR <30 mL/min)
Severe hepatic disease
Hypersensitivity to sitagliptin or metformin
Conditions predisposing to lactic acidosis
Pregnancy and lactation
Administration:
Administer orally with meals
Swallow whole with water
Do not skip meals
Drug Interactions:
Increased risk of hypoglycemia with insulin or sulfonylureas
Metformin interaction with iodinated contrast media
Reduced efficacy with corticosteroids and diuretics
Alcohol increases risk of lactic acidosis
Compatibility:
Suitable for combination with insulin or other oral antidiabetic agents
Compatible with comprehensive diabetes management protocols
Stability / Storage:
Store below 25°C
Protect from heat, moisture, and light
Keep out of reach of children
Precautions:
Risk of lactic acidosis (metformin component)
Monitor renal function regularly
Risk of pancreatitis (rare with sitagliptin)
Monitor blood glucose levels
Use cautiously in elderly patients
Suspend before surgery or contrast imaging procedures
Side Effects:
Common:
Gastrointestinal disturbances (nausea, diarrhea)
Headache
Hypoglycemia (when used with other agents)
Uncommon:
Dizziness
Fatigue
Serious (Rare):
Lactic acidosis
Pancreatitis
Hypersensitivity reactions
Important Note:
SITA-H is a fixed-dose combination for effective glycemic control in Type 2 Diabetes Mellitus. It should be used under strict medical supervision. This information is intended for healthcare professionals and educational purposes only.